DeCode Genetics this week said that it has named Earl "Duke" Collier to its board of directors, effective immediately. Collier is an executive vice president at Genzyme and previously served as president of Vitas Healthcare and as a partner at the Washington, DC-based law firm Hogan and Hartson. Prior to that position, he served as deputy administrator of the Health Care Finance Administration — now the Centers For Medicare and Medicaid Services — in the US Department of Health and Human Services. He earned a BA from Yale University and a JD from the University of Virginia.
Transgenomic said this week that its board of directors has elected Craig Tuttle as the company's president and chief executive officer, effective immediately. Tuttle will be based at the company's Omaha headquarters. He will succeed Mike Summers, who served as interim chief executive officer, and who will continue as the company's chief financial officer.
Tuttle previously served as president and COO of Duke Scientific, a specialty chemistry manufacturer, where he led its sale to Fisher Healthcare in 2005. Prior to that position, he was the president of Applied Biotech, the home pregnancy test manufacturer. Before that, he ran Seradyn, a specialty chemical and diagnostic test manufacturer.
Tuttle has also held management positions with Boehringer Mannheim, Bayer Healthcare, and Cetus.
Tuttle earned a BS in biochemistry from the University of California, Los Angeles, an MS in biochemistry from the University of Colorado, and an MBA from St. Mary's College.